The following is excerpted from the question-and-answer section of the transcript.
(Questions from industry analysts are provided in full, but answers are omitted - download the transcript to see the full question-and-answer session)
Question: Boris Peaker - Rodman & Renshaw - Analyst
: Yes, hi. Thank you for taking my question. Quick question on SparVax, have you had any interaction with the FDA in terms of exactly what they are
looking for or is it just what we've heard since the last call?
Question: Boris Peaker - Rodman & Renshaw - Analyst
: And have they commented at all on the timeline or any kind of milestones that they will announce that they like it or don't like it or they want you
to go back and do something else?
Question: Boris Peaker - Rodman & Renshaw - Analyst
: Well, thank you very much.
Question: Debra Fiakas - Crystal Equity Research - Analyst
: Thank you. Just one quick housekeeping question, and then my one question, if you could just repeat the cash flow from operations, and then
comment on the White Paper, a little more detail on the White Paper that you submitted to BARDA for the IV formulation of Valortim. The proposal
that you indicated would be submitted by June 1. Do I understand correctly that this is a non-competitive situation, and also could you describe
perhaps what the decision-making timeline might be with regard to that proposal?
Question: Debra Fiakas - Crystal Equity Research - Analyst
: I'm sorry. The very first part of the question was actually if you could just repeat what your cash usage by operations was, and then my main question
is about the...
Question: Debra Fiakas - Crystal Equity Research - Analyst
: Okay, very good.
Question: Steve Brozak - WBB Securities - Analyst
: Hi, good morning gentlemen. The question basically goes back to the FDA submission, typically, and I know there is not much precedent for this,
typically you know you would be looking at something where after you would have had the contract awarded, you would have basically been in
a position where the FDA would weigh in.
What are your thoughts, because now all of a sudden it is sort of like you are getting an advantage here with the FDA, because probably a good
portion of the questions are going to be answered before you even have to worry about the contract. So even though it is being perceived a little
bit of a delay, now you have got an advantage in that you pretty much get the contract. You know what you are looking for. How do you position
yourself with that and what do you think about that type of statement?
Question: Steve Brozak - WBB Securities - Analyst
: Okay, so in a nutshell it is not -- well, I guess it would be in a situation also for investors it would be an advantage, because that are less things.
There are less unknowns how to quantify in terms of valuing your stock investment and your stock. That's would probably be an accurate statement
as well. Wouldn't it?
Question: Steve Brozak - WBB Securities - Analyst
: Great. I look forward to hearing in the future. Thank you.
| 
